The CCNDBP1 Knockout HAP1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the CCNDBP1 gene has been disrupted across a heterogeneous pool of HAP1 cells. This polyclonal format is generated without single-cell cloning, retaining the genetic diversity of the edited population while ensuring robust loss-of-function effects at the population level. The gene disruption is achieved via CRISPR/Cas9-mediated targeting, enabling researchers to study the functional consequences of CCNDBP1 ablation in a physiologically relevant cellular context. This model is ideal for genetic screening, functional genomics, and mechanistic studies of tumor suppressor pathways.
HAP1 cells are a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia line, characterized by an adherent, fibroblast-like morphology. The near-haploid karyotype, with disomy of chromosome 8, means that most genes are present in a single copy, which greatly facilitates knockout studies by eliminating the need for biallelic targeting. HAP1 cells have been widely adopted for CRISPR-based functional genomics, drug screening, and genetic interaction mapping due to their ease of culture and genetic tractability. The CCNDBP1 knockout in this background enables efficient exploration of gene function without confounding allelic compensation.
CCNDBP1 (Cyclin D1 Binding Protein 1) is a tumor suppressor that negatively regulates cell cycle progression and Wnt/??-catenin signaling. Mechanistically, CCNDBP1 binds directly to cyclin D1 and LEF1, thereby inhibiting the kinase activity of cyclin D1/CDK4 complexes and repressing LEF1-mediated transcription of Wnt target genes such as MYC and CCND1. This dual inhibitory role integrates signals from the cell cycle machinery and the Wnt pathway. The protein also interacts with Grap2 and CDKN1B, and is regulated upstream by miR-205 and MYCN. Through these interactions, CCNDBP1 serves as a critical node linking proliferation control to oncogenic transcription. Knockout of CCNDBP1 relieves this repression, leading to enhanced cell cycle entry and activation of Wnt-responsive genes.
In the HAP1 cell background, disruption of CCNDBP1 is expected to unleash unrestrained Wnt/??-catenin activity and accelerate cell proliferation. This polyclonal knockout cell population provides a versatile platform to dissect CCNDBP1??s role in tumor suppression across multiple cancer types, including hepatocellular carcinoma, leukemia, lymphoma, neuroblastoma, and colorectal cancer. The near-haploid nature of HAP1 cells ensures that even subtle phenotypes are detectable, and the polyclonal format allows assessment of population-level responses, reducing clonal biases. Researchers can use this model to validate CCNDBP1??s downstream effectors and its crosstalk with TGF-beta signaling.
Typical experimental applications include Western blotting to confirm loss of CCNDBP1 protein, RT-qPCR to assess transcriptional changes in Wnt targets, and Wnt luciferase reporter assays to measure pathway activity. Cell proliferation, apoptosis, and cell cycle flow cytometry assays can quantify functional outcomes. RNA-seq enables transcriptome-wide profiling of knockout effects, while ChIP-qPCR can determine LEF1 occupancy at target promoters. These cells are suitable for high-throughput genetic interaction screens, drug sensitivity studies, and biomarker identification. For more information or to discuss custom projects, please contact Ascent Research.
